Patents Represented by Attorney, Agent or Law Firm Thomas E. Northrup
-
Patent number: 6699682Abstract: The soporific activity of cis-9,10-octadecenoamide and other soporific fatty acid primary amides is neutralized by hydrolysis in the presence of fatty-acid amide hydrolase (FAAH). Hydrolysis of cis-9,10-octadecenoamide by FAAH leads to the formation of oleic acid, a compound without soporific activity. FAAH has be isolated and the gene encoding FAAH has been cloned, sequenced, and used to express recombinant FAAH. Inhibitors of FAAH are disclosed to block the hydrolase activity.Type: GrantFiled: June 28, 2001Date of Patent: March 2, 2004Assignee: The Scripps Research InstituteInventors: Norton B. Gilula, Benjamin F. Cravatt, Richrd A. Lerner
-
Patent number: 6677435Abstract: The present invention provides a compound that includes an active therapeutic agent attached to a blocking moiety that is sensitive to the catalytic action of molecules having retro-aldol and retro-Michael catalytic activity, methods for making such compounds and methods of converting such compounds to active therapeutic agents using molecules having aldolase activity.Type: GrantFiled: June 18, 2001Date of Patent: January 13, 2004Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, III, Doron Shabat, Christoph Rader, Benjamin List, Richard A. Lerner
-
Patent number: 6613734Abstract: The present invention discloses useful surfactant molecules including polypeptides, proteins, and a variety of other organic molecules, as well as methods of making and using same. Surfactant compositions, including liposomal surfactant compositions, are also disclosed. In one preferred embodiment, a pulmonary surfactant composition comprises one or more pharmaceutically acceptable phospholipids admixed with a polypeptide comprising about 10 to 60 amino acid residues, wherein the polypeptide includes a sequence constituted by alternating groupings of charged amino acid residues and uncharged amino acid residues.Type: GrantFiled: June 7, 1995Date of Patent: September 2, 2003Assignee: The Scripps Research InstituteInventors: Charles G. Cochrane, Susan D. Revak
-
Patent number: 6610512Abstract: Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating gene expression are also provided.Type: GrantFiled: January 28, 2000Date of Patent: August 26, 2003Assignee: The Scripps Research InstituteInventor: Carlos F. Barbas
-
Patent number: 6589766Abstract: Catalytic antibodies, including 38C2 and 33F12, are capable of efficiently catalyzing a wide variety of ketone-ketone, ketone-aldehyde, aldehyde-ketone, and aldehyde-aldehyde intermolecular aldol reactions, and in some cases to catalyze their subsequent dehydration to yield aldol condensation products. A number of intramolecular aldol reactions have also been defined. Catalysis of all intramolecular aldol reactions examined yields the corresponding condensation products.Type: GrantFiled: September 25, 2001Date of Patent: July 8, 2003Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Richard A. Lerner, Guofu Zhong, Benjamin List
-
Patent number: 6586236Abstract: A modified filamentous phage that contains a gene for a wild type phage coat protein and a gene for a synthetic phage coat protein is provided. Uses of the modified phage and kits containing the phage are also provided.Type: GrantFiled: November 27, 2001Date of Patent: July 1, 2003Assignee: The Scripps Research InstituteInventor: Angray S. Kang
-
Patent number: 6551789Abstract: A method of characterizing a biological sample is provided. The method includes the steps of contacting the sample with at least two receptor molecules to generate a first pattern of reactivity and comparing that pattern to a second reactivity pattern generated by a known sample and indicative of oncogene expression.Type: GrantFiled: October 26, 1999Date of Patent: April 22, 2003Assignee: The Scripps Research InstituteInventor: Henry L. Niman
-
Patent number: 6476198Abstract: The present invention relates to multispecific and multivalent antigen-binding polypeptides and methods for producing them.Type: GrantFiled: June 27, 1995Date of Patent: November 5, 2002Assignee: The Scripps Research InstituteInventor: Angray Singh Kang
-
Patent number: 6395275Abstract: The present invention describes synthetic human monoclonal antibodies that immunoreact with and neutralize human immunodeficiency virus (HIV). The synthetic monoclonal antibodies of this invention exhibit enhanced binding affinity and neutralization ability to gp120. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell lines for producing the monoclonal antibodies.Type: GrantFiled: July 6, 2000Date of Patent: May 28, 2002Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner
-
Patent number: 6368839Abstract: Antibodies that catalyze the aldol reaction are generated by immunization with a reactive compound that covalently traps a Lysine (Lys) residue in the binding pocket of the antibody by formation of a stable vinylogous amide, i.e., a covalent antibody/hapten complex. The resultant catalytic antibodies employ a catalytic mechanism which mimics the catalytic mechanism employed by natural class I aldolase enzymes.Type: GrantFiled: November 16, 1999Date of Patent: April 9, 2002Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, III, Richard A. Lerner, Juergen Wagner
-
Patent number: 6326176Abstract: Catalytic antibodies, including 38C2 and 33F12, are capable of efficiently catalyzing a wide variety of ketone-ketone, ketone-aldehyde, aldehyde-ketone, and aldehyde-aldehyde intermolecular aldol reactions, and in some cases to catalyze their subsequent dehydration to yield aldol condensation products. A number of intramolecular aldol reactions have also been defined. Catalysis of all intramolecular aldol reactions examined yields the corresponding condensation products.Type: GrantFiled: May 18, 2000Date of Patent: December 4, 2001Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Richard A. Lerner, Guofu Zhong, Benjamin List
-
Patent number: 6323004Abstract: A modified filamentous phage that contains a gene for a wild type phage coat protein and a gene for a synthetic phage coat protein is provided. Uses of the modified phage and kits containing the phage are also provided.Type: GrantFiled: May 1, 2000Date of Patent: November 27, 2001Assignee: The Scripps Research InstituteInventor: Angray S. Kang
-
Patent number: 6309881Abstract: Nine efficient aldolase antibodies were generated using hapten 2. This hapten combines, in a single molecule, structural components employed for reactive immunization with structural components employed for forming a transition state analog of the aldol reaction. Characterization of two of these antibodies reveals that they are highly proficient (up to 1000-fold better than any other antibody catalyst) and enantioselective catalysts for aldol and retro-aldol reactions and exhibit enantio- and diastereo-selectivities opposite that of antibody 38C2.Type: GrantFiled: April 2, 2001Date of Patent: October 30, 2001Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Richard A. Lerner, Guofu Zhong
-
Patent number: 6281354Abstract: The field of this invention is antitumor antibiotics. More particularly, the present invention relates to analogs of duocarmycin and CC-1065, which analogs have antitumor antibiotics activity.Type: GrantFiled: November 9, 1999Date of Patent: August 28, 2001Assignee: The Scripps Research InstituteInventor: Dale L. Boger
-
Patent number: 6271015Abstract: The soporific activity of cis-9,10-octadecenoamide and other soporific fatty acid primary(amides is neutralized by hydrolysis in the presence of fatty-acid amide hydrolase (FAAH). Hydrolysis of cis-9,10-octadecenoamide by FAAH leads to the formation of oleic acid, a compound without soporific activity. FAAH has be isolated and the gene encoding FAAH has been cloned, sequenced, and used to express recombinant FAAH. Inhibitors of FAAH are disclosed to block the hydrolase activity.Type: GrantFiled: November 4, 1996Date of Patent: August 7, 2001Assignee: The Scripps Research InstituteInventors: Norton B. Gilula, Benjamin F. Cravatt, Richard A. Lerner
-
Patent number: 6268488Abstract: The present invention provides a compound that includes an active therapeutic agent attached to a blocking moiety that is sensitive to the catalytic action of molecules having retro-aldol and retro-Michael catalytic activity, methods for making such compounds and methods of converting such compounds to active therapeutic agents using molecules having aldolase activity.Type: GrantFiled: May 25, 1999Date of Patent: July 31, 2001Inventors: Carlos F. Barbas, III, Doron Shabat, Christoph Rader, Benjamin List, Richard A. Lerner
-
Patent number: 6261558Abstract: The present invention describes synthetic human monoclonal antibodies that immunoreact with and neutralize human immunodeficiency virus (HIV). The synthetic monoclonal antibodies of this invention exhibit enhanced binding affinity and neutralization ability to gp120. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell lines for producing the monoclonal antibodies.Type: GrantFiled: February 20, 1996Date of Patent: July 17, 2001Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner
-
Patent number: 6251931Abstract: Oleamide is an endogenous fatty acid primary amide that possesses sleep-inducing properties in animals and has been shown to effect seratonergic systems and block gap junction communication in a structurally specific manner. Certain agents can serve both as an oleamide agonist and as an inhibitor of fatty acid amide hydrolase. Fatty acid amide hydrolase is responsible for the rapid inactivation of oleamide in vivo. The structural features of oleamide required for inhibition of gap junction-mediated chemical and electrical transmission in rat glial cells are defined. Effective inhibitors fall into two classes of fatty acid primary amides of which oleamide and arachidonamide are the prototypical members. Of these two, oleamide constitutes the most effective and its structural requirements for inhibition of the gap junction are well defined.Type: GrantFiled: April 19, 2000Date of Patent: June 26, 2001Assignee: The Scripps Research InstituteInventors: Dale L. Boger, Norton B. Gilula, Richard A. Lerner, Benjamin F. Cravatt
-
Patent number: 6232080Abstract: The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody molecule. A therapeutic composition comprising anti-LBP antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: GrantFiled: May 19, 1998Date of Patent: May 15, 2001Assignee: The Scripps Research InstituteInventors: Theo Kirkland, Peter Tobias, Richard Ulevitch, Ann Moriarty, Didier Leturcq
-
Patent number: 6190908Abstract: A modified filamentous phage that contains a gene for a wild type phage coat protein and a gene for a synthetic phage coat protein is provided. Uses of the modified phage and kits containing the phage are also provided.Type: GrantFiled: December 24, 1998Date of Patent: February 20, 2001Assignee: The Scripps Research InstituteInventor: Angray S. Kang